Microvena's Trap VFS
This article was originally published in The Gray Sheet
Executive SummaryVascular filtration system for use during angioplasty and stenting procedures in saphenous vein bypass grafts is anticipated to debut in Europe in the fourth quarter following CE mark approval in July. Phase I multi-center randomized U.S. trials commenced in June, and enrollment should be complete by the end of year, the firm says. In contrast to distal protection systems that use occlusion balloons, the device's self-expanding nitinol filter, placed downstream of the target lesion, captures debris while allowing blood to continue to flow uninterrupted, according to the company. Microvena expects to launch the Trap in the U.S. by late 2001 or early 2002
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.